

The Growing Exposure of Aimovig®

The preventive migraine treatment with the most extensive real-world patient experience



Aimovig (erenumab)

- Is the **1st preventive migraine treatment approved** by the FDA, EMA, Swissmedic and Australian TGA
- **Has consistently shown to reduce monthly migraine days**, including in more difficult to treat populations, with many patients achieving at least a 50% reduction¹⁻⁴
- **Demonstrated sustained efficacy and safety** for people living with migraine, which remains the third most common disease in the world⁵
- **Can be self-administered** or by another trained person every four weeks with the SureClick® autoinjector



Aimovig's fast growing real world experience




Aimovig is the migraine prevention treatment with the **largest and longest exposure in the market**



As of April 2019, an estimated **220,000** patients worldwide have been prescribed Aimovig.⁶


Aimovig® is currently available in 29 countries worldwide



Unique mode of action

Aimovig is the **first and only** treatment approved by the EMA and the FDA for the prevention of migraine in adults targeting the calcitonin gene-related peptide receptor (CGRP-R).

CGRP is a protein that binds to the CGRP receptor complex and is thought to be responsible for transmitting the pain signals associated with migraine.^{7,8}



© 2018 Amgen Inc. All rights reserved. Not for reproduction. www.amgen.com Used with permission



Growing clinical evidence on Aimovig's long-term efficacy and safety

2/3

More than two-thirds of chronic migraine patients converted to episodic migraine by the last dose received (Results from a 52-week, multicenter study, OLE, NCT02174861).⁹



In the one-year extension of the Phase 3 STRIVE study, the efficacy data showed sustained benefits over 52 weeks.¹⁰

References:

1. Reuter, U et al. Efficacy and safety of erenumab in episodic migraine patients with 2-4 prior preventive treatment failures: Results from the Phase 3b LIBERTY study. Emerging science abstract presented at AAN, 24 April 2018, Los Angeles.
2. Goadsby PJ et al. Trial of Erenumab for Episodic Migraine. N Engl J Med. 2017 Nov 30;377(22):2123-2132.
3. Dodick DW et al. ARISE: A Phase 3 randomized trial of erenumab for episodic migraine. Cephalalgia. 2018 May;38(6):1026-1037.
4. Tepper S, Ashina M, Reuter U. Safety and efficacy of erenumab for preventive treatment of chronic migraine: A randomised, double-blind, placebo-controlled phase 2 trial. Lancet Neurol 2017; 16: 425-434.
5. Migraine Research Foundation. Migraine facts. <https://migraineresearchfoundation.org/about-migraine/migraine-facts/>. Accessed March 2019.
6. Data on File. Novartis. April 2019.
7. Bigal ME, Walter S, Rapoport AM. Calcitonin gene-related peptide (CGRP) and migraine: Current understanding and state of development. Headache. 2013;53(8):1230-1244.
8. Lassen LH, Hadersley PA, Jacobsen VB, et al. CGRP may play a causative role in migraine. Cephalalgia. 2002;22(1):54-61.
9. Lipton R, Tepper S, Silberstein S, et al. Presented at the 71st Annual Meeting of the American Academy of Neurology; May 4-10, 2019; Philadelphia, PA.
10. Chou D, Goadsby P, Reuter U, et al. Presented at the 71st Annual Meeting of the American Academy of Neurology; May 4-10, 2019; Philadelphia, PA.